文献速递白血病MDS 与骨髓增殖性肿瘤

世界卫生组织定义嗜酸性粒细胞疾病:2022年诊断、风险分层与管理更新

World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
PubMed 文献 · Am J Hematol · 2021-10-08

该综述更新了WHO定义的嗜酸性粒细胞疾病的诊断、风险分层与管理。嗜酸性粒细胞增多定义为外周血嗜酸性粒细胞计数大于1.5×10^9/L,需排除继发原因。诊断依赖形态学、细胞遗传学、FISH、NGS和流式免疫表型。治疗目标为减轻嗜酸性粒细胞介导的器官损伤,PDGFRA/PDGFRB重排者对伊马替尼敏感,淋巴细胞变异型HE和HES首选糖皮质激素,Mepolizumab获批用于特发性HES。

要点

  • 嗜酸性粒细胞增多定义为外周血嗜酸性粒细胞计数大于1.5×10^9/L。
  • 诊断需排除继发原因,并采用形态学、细胞遗传学、FISH、NGS和流式免疫表型检测克隆性证据。
  • PDGFRA或PDGFRB重排者对伊马替尼敏感,淋巴细胞变异型HE和HES首选糖皮质激素。

核心结论

  • 嗜酸性粒细胞疾病涵盖非血液学和血液学疾病,诊断需排除继发原因并识别克隆性证据,治疗目标为减轻嗜酸性粒细胞介导的器官损伤。

研究设计与样本

  • 综述更新,基于2016年WHO半分子分类方案,汇总诊断、风险分层和管理建议。

主要发现

  • 嗜酸性粒细胞增多定义为外周血嗜酸性粒细胞计数大于1.5×10^9/L。
  • PDGFRA或PDGFRB重排的髓系/淋系肿瘤对伊马替尼敏感。
  • Mepolizumab获美国FDA批准用于特发性HES。

关键数值与推荐

  • 嗜酸性粒细胞增多定义为外周血嗜酸性粒细胞计数大于1.5×10^9/L。
  • 对于轻度嗜酸性粒细胞增多(如小于1.5×10^9/L)且无器官受累症状或体征者,可采取观察等待策略并密切随访。
  • PDGFRA或PDGFRB重排的识别至关重要,因该类疾病对伊马替尼高度敏感。
  • 糖皮质激素是淋巴细胞变异型HE和HES的一线治疗。
  • 羟基脲和干扰素-α可作为HES的初始治疗及类固醇难治病例的有效选择。

临床怎么用

  • 对嗜酸性粒细胞增多患者,先排除继发原因,再通过形态学、细胞遗传学、FISH、NGS和流式免疫表型评估克隆性。
  • 识别PDGFRA或PDGFRB重排以指导伊马替尼治疗。
  • 淋巴细胞变异型HE和HES首选糖皮质激素,难治病例可选用羟基脲或干扰素-α。
  • 特发性HES可使用Mepolizumab;benralizumab、JAK2和FGFR1抑制剂等靶向治疗正在研究中。

局限性

  • 本文为综述,未报告原始研究样本量、P值等数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: The eosinophilias encompass a broad range of nonhematologic (secondary or reactive) and hematologic (primary or clonal) disorders with potential for end-organ damage. DIAGNOSIS: Hypereosinophilia (HE) has generally been defined as a peripheral blood eosinophil count greater than 1.5 × 109 /L. After exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on morphologic review of the blood and marrow, standard cytogenetics, fluorescence in situ hybridization, next generation sequencing gene assays, and flow immunophenotyping to detect histopathologic or clonal evidence for an acute or chronic hematolymphoid neoplasm. RISK STRATIFICATION: Disease prognosis relies on identifying the subtype of eosinophilia. After evaluation of secondary causes of eosinophilia, the 2016 World Health Organization endorses a semi-molecular classification scheme of disease subtypes. This includes the major category "myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2", and the myeloproliferative neoplasm subtype, "chronic eosinophilic leukemia, not otherwise specified" (CEL, NOS). Lymphocyte-variant HE is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic syndrome (HES) is a diagnosis of exclusion. RISK-ADAPTED THERAPY: The goal of therapy is to mitigate eosinophil-mediated organ damage. For patients with milder forms of eosinophilia (eg, < 1.5 × 109 /L) without symptoms or signs of organ involvement, a watch and wait approach with close follow-up may be undertaken. Identification of rearranged PDGFRA or PDGFRB is critical because of the exquisite responsiveness of these diseases to imatinib. Corticosteroids are first-line therapy for patients with lymphocyte-variant HE and HES. Hydroxyurea and interferon-α have demonstrated efficacy as initial treatment and in steroid-refractory cases of HES. Mepolizumab, an interleukin-5 (IL-5) antagonist monoclonal antibody, was recently approved by the US Food and Drug Administration for patients with idiopathic HES. The use of the IL-5 receptor antibody benralizumab, as well as other targeted therapies such as JAK2 and FGFR1 inhibitors, is under active investigation.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2021. PMID: 34533850. doi:10.1002/ajh.26352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。